SAMUEL RAY DENMEADE, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D44576
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-8964
(410) 614-8397
(410) 614-8397
Personal information
See more information about SAMUEL RAY DENMEADE at radaris.comName
Address
Phone
5112 Little Creek Dr, Ellicott City, MD 21043
Ellicott City, MD
5112 Little Creek Dr, Ellicott City, MD 21043
Professional information
Dr. Samuel R Denmeade, Ellicott City MD - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
5112 Little Creek Dr, Ellicott City 21043
1650 Orleans St, Baltimore 21287
(410) 502-3941 (Phone), (410) 955-0125 (Fax)
SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
1650 Orleans St SUITE 389, Baltimore 21287
(410) 955-8839 (Phone), (410) 955-0960 (Fax)
600N S Wolfe St, Baltimore 21231
(410) 955-8964 (Phone), (410) 955-8587 (Fax)
1650 Orleans St, Baltimore 21287
(410) 502-3941 (Phone), (410) 955-0125 (Fax)
SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
1650 Orleans St SUITE 389, Baltimore 21287
(410) 955-8839 (Phone), (410) 955-0960 (Fax)
600N S Wolfe St, Baltimore 21231
(410) 955-8964 (Phone), (410) 955-8587 (Fax)
Certifications:
Internal Medicine, 1992, Medical Oncology, 1995
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
5112 Little Creek Dr, Ellicott City 21043
1650 Orleans St, Baltimore 21287
600N S Wolfe St, Baltimore 21231
SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
1650 Orleans St SUITE 389, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
1650 Orleans St, Baltimore 21287
600N S Wolfe St, Baltimore 21231
SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT JOHNS HOPKINS
1650 Orleans St SUITE 389, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Columbia University / College of Physicians And Surgeons
Graduated: 1989
The University Of Chicago Medical Center
The Johns Hopkins Hospital
Columbia University / College of Physicians And Surgeons
Graduated: 1989
The University Of Chicago Medical Center
The Johns Hopkins Hospital
Samuel Ray Denmeade, Baltimore MD
Specialties:
Emergency Medicine, Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N Broadway St, Baltimore, MD 21287 Bunting Blaustein Cancer Res.
1650 Orleans St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287
401 N Broadway St, Baltimore, MD 21287 Bunting Blaustein Cancer Res.
1650 Orleans St, Baltimore, MD 21287 JHU Oncology
600 N Wolfe St, Baltimore, MD 21287
Education:
Columbia University (1989)
Samuel Ray Denmeade, Baltimore MD
Specialties:
Oncologist
Address:
1650 Orleans St, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
600 N Wolfe St, Baltimore, MD 21287
600 N Wolfe, Baltimore, MD 21287
Education:
Columbia University, College of Physicians and Surgeons - Doctor of Medicine
Johns Hopkins Hospital - Fellowship - Oncology (Internal Medicine)
Bernard Mitchell Hospital-University of Chicago Hospitals - Residency - Internal Medicine
Bernard Mitchell Hospital-University of Chicago Hospitals - Internship - Internal Medicine
Johns Hopkins Hospital - Fellowship - Oncology (Internal Medicine)
Bernard Mitchell Hospital-University of Chicago Hospitals - Residency - Internal Medicine
Bernard Mitchell Hospital-University of Chicago Hospitals - Internship - Internal Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Oncology (Internal Medicine)
Tissue Specific Prodrug
US Patent:
6504014, Jan 7, 2003
Filed:
Jun 7, 2000
Appl. No.:
09/588822
Inventors:
John T. Isaacs - Baltimore MD
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Assignee:
The John Hopkins University - Baltimore MD
International Classification:
C07K 1600
US Classification:
5303917, 549236
Abstract:
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene--lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
Tissue Specific Prodrug
US Patent:
6410514, Jun 25, 2002
Filed:
Jun 7, 2000
Appl. No.:
09/588921
Inventors:
John T. Isaacs - Baltimore MD
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 3800
US Classification:
514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530326, 530327, 530328, 530329, 530330
Abstract:
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene--lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
Tissue Specific Prodrug
US Patent:
6265540, Jul 24, 2001
Filed:
May 19, 1998
Appl. No.:
9/081707
Inventors:
John T. Isaacs - Baltimore MD
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Samuel R. Denmeade - Baltimore MD
S. Brogger Christensen - Copenhagen, DK
Hans Lilja - Skanor, SE
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C07K 1600
US Classification:
530326
Abstract:
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific antigen (PSA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSA, the therapeutic drugs are activated and exert their toxicity. Novel sesquiterpene-. gamma. -lactones are also provided by the invention, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.